PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 11724337-0 2001 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. 9-hydroxyellipticine 0-20 tumor protein p53 Homo sapiens 88-91 15548707-6 2004 On the basis of this analysis, formation of 9-hydroxyellipticine and 7-hydroxyellipticine was attributable to CYP1A1/2, whereas production of 13-hydroxyellipticine and ellipticine N(2)-oxide, the metabolites responsible for formation of two major DNA adducts, was attributable to CYP3A4. 9-hydroxyellipticine 44-64 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 110-118 15548707-7 2004 Using recombinant human enzymes, oxidation of ellipticine to 9-hydroxyellipticine and 7-hydroxyellipticine by CYP1A1/2 and to 13-hydroxyellipticine and N(2)-oxide by CYP3A4 was corroborated. 9-hydroxyellipticine 61-81 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 110-118 12570841-1 2003 The hydroxy group in 9-hydroxyellipticines increases the apparent affinity for DNA, stabilisation of toposiomerase II-DNA cleavable complex, oxidation to reactive quinone-imine intermediates, phosphorylation of p53 suppressor proteins and cytotoxicity relative to the parent ellipticines. 9-hydroxyellipticine 21-42 tumor protein p53 Homo sapiens 211-214 23293027-5 2013 Here we report that a number of the ellipticines, including 9-hydroxyellipticine, are potent and specific inhibitors of Pol-I transcription, with IC(50) in vitro and in cells in the nanomolar range. 9-hydroxyellipticine 60-80 DNA polymerase iota Homo sapiens 120-125 17159771-8 2006 Using the reconstituted enzymatic system, we demonstrated that the detoxication ellipticine metabolites, 7-hydroxyellipticine and 9-hydroxyellipticine, are mainly generated by CYP1A1 and 1A2, while those responsible for DNA binding, 13-hydroxy-, 12-hydroxyellipticine and ellipticine N(2)-oxide, by CYP3A1 and 2C3. 9-hydroxyellipticine 130-150 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 176-190 11724337-3 2001 We examined whether 9-hydroxyellipticine (9HE), a cytotoxic agent, affected the tertiary structure of mutant p53 and DNA binding characteristics. 9-hydroxyellipticine 20-40 tumor protein p53 Homo sapiens 109-112 11724337-3 2001 We examined whether 9-hydroxyellipticine (9HE), a cytotoxic agent, affected the tertiary structure of mutant p53 and DNA binding characteristics. 9-hydroxyellipticine 42-45 tumor protein p53 Homo sapiens 109-112 3729973-8 1986 The cytochrome P-450c inhibitor 9-hydroxyellipticine inhibited conversion of pentachlorophenol to tetrachlorobenzenediols by HCB and beta-naphthoflavone induced micromes. 9-hydroxyellipticine 32-52 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 4-21 9883907-2 1998 We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function. 9-hydroxyellipticine 21-41 tumor protein p53 Homo sapiens 187-190 9883907-2 1998 We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function. 9-hydroxyellipticine 21-41 tumor protein p53 Homo sapiens 262-265 9883907-2 1998 We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function. 9-hydroxyellipticine 43-47 tumor protein p53 Homo sapiens 187-190 9883907-2 1998 We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function. 9-hydroxyellipticine 43-47 tumor protein p53 Homo sapiens 262-265 9883907-5 1998 We conclude that 9-HE may exert a strong inhibitory effect on telomerase activity possibly through inhibition of protein kinases rather than through restoration of functional wild-type p53. 9-hydroxyellipticine 17-21 tumor protein p53 Homo sapiens 185-188 8975635-9 1996 Inhibition of EROD and PROD by 9-hydroxyellipticine, a specific inhibitor of rat hepatic cytochrome P4501A1, revealed that PROD induction by TCDD and other P4501A-inducers was probably a result of a broader substrate specificity of chick embryo P4501A. 9-hydroxyellipticine 31-51 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 89-107 7591958-0 1995 Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. 9-hydroxyellipticine 45-65 tumor protein p53 Homo sapiens 14-17 7591958-2 1995 We found that ellipticine and 9-hydroxyellipticine (9HE), antitumor alkaloids, caused selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 (human colon cancer cell line) in a concentration-dependent manner from 0.1 to 100 microM. 9-hydroxyellipticine 30-50 tumor protein p53 Homo sapiens 110-113 7591958-2 1995 We found that ellipticine and 9-hydroxyellipticine (9HE), antitumor alkaloids, caused selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 (human colon cancer cell line) in a concentration-dependent manner from 0.1 to 100 microM. 9-hydroxyellipticine 52-55 tumor protein p53 Homo sapiens 110-113 10737712-0 2000 Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations. 9-hydroxyellipticine 19-39 tumor protein p53 Homo sapiens 107-110 10737712-1 2000 Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation. 9-hydroxyellipticine 33-53 tumor protein p53 Homo sapiens 145-148 10737712-1 2000 Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation. 9-hydroxyellipticine 33-53 tumor protein p53 Homo sapiens 188-191 10737712-1 2000 Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation. 9-hydroxyellipticine 55-59 tumor protein p53 Homo sapiens 145-148 10737712-1 2000 Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation. 9-hydroxyellipticine 55-59 tumor protein p53 Homo sapiens 188-191 10737712-3 2000 Exposure of cells to 9-HE at a relatively low concentration of 1 microM induced almost no cell death but was sufficient to restore wt p53 activity, as evidenced by an induction of endogenous p21WAF1/CIP1 concomitant with G1 and G2/M arrests in cell-cycle progression. 9-hydroxyellipticine 21-25 tumor protein p53 Homo sapiens 134-137 10737712-6 2000 These effects of 9-HE were specific for several cell lines containing mt p53 and were not observed in p53-negative or wt p53 expressing cells. 9-hydroxyellipticine 17-21 tumor protein p53 Homo sapiens 73-76 10652599-0 1999 Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. 9-hydroxyellipticine 80-100 tumor protein p53 Homo sapiens 7-10 10652599-2 1999 Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE). 9-hydroxyellipticine 161-182 tumor protein p53 Homo sapiens 30-33 10652599-2 1999 Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE). 9-hydroxyellipticine 161-182 tumor protein p53 Homo sapiens 110-113 10652599-2 1999 Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE). 9-hydroxyellipticine 184-187 tumor protein p53 Homo sapiens 30-33 10652599-2 1999 Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE). 9-hydroxyellipticine 184-187 tumor protein p53 Homo sapiens 110-113 8240392-2 1993 9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes. 9-hydroxyellipticine 0-21 aryl hydrocarbon receptor Rattus norvegicus 107-137 8240392-2 1993 9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes. 9-hydroxyellipticine 0-21 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 173-201 8240392-2 1993 9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes. 9-hydroxyellipticine 0-21 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 212-215 8240392-2 1993 9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes. 9-hydroxyellipticine 23-28 aryl hydrocarbon receptor Rattus norvegicus 107-137 8240392-2 1993 9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes. 9-hydroxyellipticine 23-28 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 173-201 8240392-2 1993 9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes. 9-hydroxyellipticine 23-28 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 212-215 8240392-3 1993 In this study, the effects of 9-OHE on the transformation of the rat hepatic cytosolic Ah receptor to a form that binds the xenobiotic responsive enhancer element-3 (XRE-3) of the cytochrome P4501A1 gene was investigated. 9-hydroxyellipticine 30-35 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 180-198 1420465-2 1992 The reactions, which involve the formation of 9-oxo-ellipticine and the addition of a nucleophilic acid on the C10 site of the heterocyclic system, have been used to measure 9-OH-E quantitatively by colorimetry in solution and by reflection on paper surfaces. 9-hydroxyellipticine 174-180 homeobox C10 Homo sapiens 111-114 6692492-0 1984 Induction by 9-hydroxyellipticine of aryl hydrocarbon hydroxylase in perinatal rat liver and in primary fetal hepatocytes in culture. 9-hydroxyellipticine 13-33 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 37-65 6087804-2 1984 Purified cytochrome P-448 (LM4), but not cytochrome P-450 (LM2), catalysed the O-de-ethylation of ethoxyresorufin in a reaction that was markedly inhibited by 9-hydroxyellipticine. 9-hydroxyellipticine 159-179 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 9-25 3996731-2 1985 An excellent direct correlation (r = 0.95) has been observed between ethoxyresorufin O-deethylase and the metabolic activation of benzo[a]pyrene to mutagens when the fraction of cytochromes P-450 present as cytochrome P-448 was altered by the administration of phenobarbitone and 3-methylcholanthrene alone or in combination with 9-hydroxyellipticine. 9-hydroxyellipticine 330-350 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 207-223 6692492-1 1984 In neonatal and, to a lesser extent, in fetal rat liver, 9-hydroxyellipticine was able to promote the induction of cytochrome P-450, supporting especially aryl hydrocarbon hydroxylase (AHH) but not aldrin epoxidase activity. 9-hydroxyellipticine 57-77 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 115-131 6692492-1 1984 In neonatal and, to a lesser extent, in fetal rat liver, 9-hydroxyellipticine was able to promote the induction of cytochrome P-450, supporting especially aryl hydrocarbon hydroxylase (AHH) but not aldrin epoxidase activity. 9-hydroxyellipticine 57-77 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 155-183 6692492-1 1984 In neonatal and, to a lesser extent, in fetal rat liver, 9-hydroxyellipticine was able to promote the induction of cytochrome P-450, supporting especially aryl hydrocarbon hydroxylase (AHH) but not aldrin epoxidase activity. 9-hydroxyellipticine 57-77 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 185-188 7181861-2 1982 The two forms of the cytochrome have different substrate specificities; cytochrome P-450 has one type 1 substrate-binding site that can accommodate a large variety of substrates, but in contrast cytochrome P-448 may possess two type 1 substrate-binding sites, one of which is different to that of cytochrome P-450 in that it shows a specificity for substrates such as safrole and 9-hydroxy-ellipticine. 9-hydroxyellipticine 380-401 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 72-88 7151231-2 1982 Biphenyl displaced the 9-hydroxyellipticine ligand from cytochrome P-448 leading to increased free cytochrome, but with no corresponding increase in mixed-function oxidase activity when biphenyl was used as substrate. 9-hydroxyellipticine 23-43 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 56-72 7151231-4 1982 Administration of 9-hydroxyellipticine to safrole-pretreated rats inhibited the cytochrome P-448-catalysed activity, but had no effect on the cytochrome P-450-catalysed activity. 9-hydroxyellipticine 18-38 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 80-96 7151231-6 1982 The type I substrate biphenyl displaced both the safrole carbene and the 9-hydroxyellipticine ligands from cytochrome P-448 resulting in increased free cytochrome. 9-hydroxyellipticine 73-93 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 107-123 7285236-3 1981 9-Hydroxyellipticine (9-OHE) interacts with human liver cytochrome P-450 exhibiting a type II spectrum (lambda max: 428 nm, Ks = 1.1 microM). 9-hydroxyellipticine 0-20 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 56-72 7172416-0 1982 The mutagenicity of 9-hydroxyellipticine and its induction of cytochrome P-448 activity in rat liver microsomes. 9-hydroxyellipticine 20-40 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 62-78 7172416-1 1982 Administration of a single dose of the inhibitor of the hepatic mixed function oxidases, 9-hydroxyellipticine (9-OHE), resulted in a marked increase in the cytochrome P-448 catalysed activities of ethoxyresorufin O-deethylase, biphenyl 2-hydroxylase and activation of benzo[a]pyrene to mutagens. 9-hydroxyellipticine 89-109 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 156-172 7172416-1 1982 Administration of a single dose of the inhibitor of the hepatic mixed function oxidases, 9-hydroxyellipticine (9-OHE), resulted in a marked increase in the cytochrome P-448 catalysed activities of ethoxyresorufin O-deethylase, biphenyl 2-hydroxylase and activation of benzo[a]pyrene to mutagens. 9-hydroxyellipticine 111-116 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 156-172 7172416-4 1982 It is concluded that 9-OHE may also act as an inducer of the hepatic microsomal mixed function oxidases, selectively inducing the synthesis of cytochrome P-448. 9-hydroxyellipticine 21-26 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 143-159 7285236-3 1981 9-Hydroxyellipticine (9-OHE) interacts with human liver cytochrome P-450 exhibiting a type II spectrum (lambda max: 428 nm, Ks = 1.1 microM). 9-hydroxyellipticine 22-27 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 56-72 7428105-0 1980 Inhibition of cytochrome P-448 mixed function oxidase activity following administration of 9-hydroxyellipticine to rats. 9-hydroxyellipticine 91-111 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 14-30 7428105-3 1980 Following the pretreatment of rats intraperitoneally with 9-hydroxyellipticine and phenobarbitone, the cytochrome P-448-specific enzyme activity, ethoxyresorufin O-deethylase, was 50% inhibited in vitro but cytochrome P-450, cytochrome P-450 reductase, and other mixed function oxidase activities were unaffected. 9-hydroxyellipticine 58-78 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 103-119 7428105-1 1980 The in vitro inhibitor of mixed-function oxidation, 9-hydroxyellipticine, non-competitively inhibited the binding of the type II substrate, aniline, to cytochrome P-448 of hepatic microsomal preparations from rats pretreated with 3-methylcholanthrene. 9-hydroxyellipticine 52-72 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 152-168 7428105-3 1980 Following the pretreatment of rats intraperitoneally with 9-hydroxyellipticine and phenobarbitone, the cytochrome P-448-specific enzyme activity, ethoxyresorufin O-deethylase, was 50% inhibited in vitro but cytochrome P-450, cytochrome P-450 reductase, and other mixed function oxidase activities were unaffected. 9-hydroxyellipticine 58-78 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 207-251 7428105-4 1980 With rats pretreated with 9-hydroxyellipticine and 3-methylcholanthrene, inhibition of ethoxyresorufin O-deethylase was 90%, and cytochrome P-450/P-448, cytochrome P-450 reductase, biphenyl 2- and 4-hydroxylase were inhibited by 30, 15, 50 and 40% respectively. 9-hydroxyellipticine 26-46 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 129-145 7428105-4 1980 With rats pretreated with 9-hydroxyellipticine and 3-methylcholanthrene, inhibition of ethoxyresorufin O-deethylase was 90%, and cytochrome P-450/P-448, cytochrome P-450 reductase, biphenyl 2- and 4-hydroxylase were inhibited by 30, 15, 50 and 40% respectively. 9-hydroxyellipticine 26-46 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 153-169 7428105-5 1980 It is concluded that 9-hydroxyellipticine administered in vivo markedly inhibits mixed-function oxidations which are specific to cytochrome P-448, but has no effect on cytochrome P-450-catalysed microsomal oxidation. 9-hydroxyellipticine 21-41 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 129-145 498356-0 1979 Interaction of 9-hydroxyellipticine with two forms of partially purified rabbit lung cytochrome P-450. 9-hydroxyellipticine 15-35 cytochrome P-450 Oryctolagus cuniculus 85-101